2017 American Transplant Congress
Long-Term Clinical Outcomes of Kidney Transplant Recipients with Body-Size Mismatch Between Recipient and Donor.
[Purpose]In living-donor kidney transplantation between large recipient and small donor, there are concerns of lower graft function and poor graft survival. Thus, we aimed to…2017 American Transplant Congress
Tangible Benefits in Caregiving Burden Among Spouses/Partners of Transplant Patients: Adding “Donor Benefit” to Live Donor Risk Assessment.
Background The mental and physical health of spouses and co-habiting partners (dyads) are highly correlated. Dialysis entails significant caregiving burden and decreases the quality of…2017 American Transplant Congress
Changes in Urinary Neutrophil Gelatinase Associated Lipocalin Combined with Urine Cytokines and Microalbuminuria as Predictors for Interstitial Fibrosis and Tubular Atrophy in Kidney Transplantation: A Matched-Pair Tissue Cohort Study.
Background: Late graft loss from interstitial fibrosis - tubular atrophy (IF/TA) continues to be the “Achilles' heel” of kidney transplantation (KT). Long-term calcineurin inhibitors (CNIs)…2017 American Transplant Congress
Deceased Donor-Initiated Non-Simultaneous Extended Altruistic Donor Chains Through the Military Share Program.
Introduction: At a recent White House Summit on organ transplantation, the Department of Defense (DoD) announced that they would direct some Military Share deceased donor…2017 American Transplant Congress
A Brief Frailty Assessment and Outcomes Among Candidates for Liver Transplantation.
Introduction: As frailty correlates with post-transplant outcomes, brief frailty measures are needed in clinical practice to appropriately risk stratify LT candidates. We used an abbreviated…2017 American Transplant Congress
Effective Targeting Plasma Cells with Daratumumab (Anti-CD38) and Mozobil (Anti-CXCR4) in a Sensitized Non-Human Primate Model.
1Surgery, Duke Transplant Center, Durham, NC; 2Surgery, Samsung Medical Center, Seoul, Korea
[Introduction] The presence of donor-specific antibodies (DSA) leads to antibody-mediated rejection (AMR) and decreased graft survival. Therefore efforts continue to be made to reduce DSA…2017 American Transplant Congress
Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.
Background: Regulatory trials assessing CMV drugs have utilized symptomatic CMV disease as the primary endpoint. However CMV disease occurs infrequently, CMV syndrome is nonspecific, and…2017 American Transplant Congress
De Novo Donor-Specific Antibodies After Allograft Nephrectomy.
Introduction: although the development of donor-specific antibodies (DSAs) is a known event after allograft nephrectomy (Nx), there are few studies describing the tempo, class and…2017 American Transplant Congress
Longitudinal Study of Donor Specific Antibodies in a Pediatric Kidney Transplant Population; Response to Optimization of Anti-Proliferative Therapy.
Children's Hospital Colorado, Aurora, CO
In 2015 we implemented surveillance donor-specific antibody (DSA) monitoring in our pediatric kidney transplant recipients (pKTR); we found that in stable pKTRs (i.e. no changes…2017 American Transplant Congress
20 and 25-Year Outcomes Following Pediatric Liver Transplantation.
Background: Improved 1,5, & 10- year survival following Pediatric Liver Transplantation (LT) has been demonstrated. However 20 and 25-year patient and graft outcomes (including cause…
- « Previous Page
- 1
- …
- 26
- 27
- 28
- 29
- 30
- …
- 181
- Next Page »